Novartis has announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing facility in Texas and marks further progress in the company’s $23-billion US investment plan announced in April 2025. 

The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations. Construction is scheduled to begin this year (2026), with the site expected to become fully operational in 2028. 

This is the second RLT facility investment announced by Novartis in 2026, joining a RLT manufacturing facility in Winter Park, Florida, announced in January 2026. That 35,000-square-foot facility will come online by 2029. Over the next five years, Novartis says it will solidify its US RLT manufacturing network, with the new sites. The company manufactures RTLs in facilities in Millburn, New Jersey, Indianapolis, Indianapolis, and Carlsbad, California. 

As part of the company’s US investment plan, Novartis had previously announced a 466,000-square-foot biomedical research facility in in San Diego, California, which joins its November 2025 announcement of a major expansion plan in North Carolina. Anticipated to open in 2027–2028, the manufacturing hub, encompassing more than 700,000 square feet between the existing campus and new facilities, includes:  

• Building a new site in Durham, North Carolina, with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging;  

• Building a new site in Morrisville, North Carolina, with one facility for the production of solid dosage tablets and capsules, including packaging; and  

• Expanding the scope of the company’s existing Durham, North Carolina, facility with the added capability to support sterile filling of biologics into syringes and vials. 

Source: Novartis